Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of Human Genome Sciences Inc. (“Human Genome” or the “Company”) (NASDAQ: HGSI) related to the proposed acquisition of the Company by GlaxoSmithKline PLC. The transaction is valued at approximately $3.6 billion or $14.25 per share.
This investigation concerns whether the Board of Directors of Human Genome breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Further, at least one analyst has set a target price for the Company’s stock at $23.00.
If you are a shareholder of Human Genome, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.